Management of acute migraine attacks: Defining the role of sumatriptan

Disease Management and Health Outcomes

Volumn 2, Issue 3, 1997, Pages 141-155

  Goa, Karen L ^a   Balfour, Julia A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001464362     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-199702030-00004     Document Type: Article

References (98)

1. Plosker GL, McTavish D. Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994 Apr; 47: 622-51
2. International Headache Society (IHS). Headache Classification Committee of the the IHS. Diagnostic criteria. Cephalalgia 1988; 8 Suppl. 7: 19-28
3. Blau JN, Drummond MF, editors. Migraine. London: Office of Health Economics, 1991
4. Saper JR. Diagnosis and symptomatic treatment of migraine. Headache 1997; 37 Suppl. 1: 1-14
5. Henry P, Michel P, Brochet B, et al. A nationwide survey of migraine in France: prevalence and clinical features in adults. Cephalalgia 1992 Aug; 12: 229-37
6. O'Brien B, Goeree R, Streiner D. Prevalence of migraine headache in Canada: a population-based survey. Int J Epidemiol 1994 Oct; 23: 1020-6
7. Solomon GD, Price KL. Burden of migraine: a review of its socioeconomic impact. Pharmacoeconomics 1997; 11 Suppl. 1: 1-10
8. Goadsby PJ, Olesen J. Diagnosis and management of migraine. BMJ 1996 May 18; 312: 1279-83
9. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 1993 Jun; 43 Suppl. 3: 6-10
10. Lipton RB, Silberstein SD, Stewart WF, et al. An update on the epidemiology of migraine. Headache 1994 Jun; 34: 319-28
11. Russell MB, Rasmussen BK, Thorvaldsen P, et al. Prevalence and sex-ratio of the subtypes of migraine. Int J Epidemiol 1995 Jun; 24: 612-8
12. Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 1993 Apr; 53: 65-72
13. Lipton RB, Ottman R, Ehrenberg BL, et al. Comorbidity of migraine: the connection between migraine and epilepsy. Neurology 1994 Oct; 44 Suppl. 7: 28-32
14. Breslau N, Merikangas K, Bowden CL. Comorbidity of migraine and major affective disorders. Neurology 1994 Oct; 44 Suppl. 7: S17-22
15. Breslau N, Davis GC. Migraine, physical health and psychiatric disorder: a prospective epidemiologic study in young adults. J Psychiatr Res 1993 Apr-Jun; 27: 211-21
16. Devlen J. Anxiety and depression in migraine. J R Soc Med 1994 Jun; 87: 338-41
17. Stewart W, Breslau N, Keck Jr PE. Comorbidity of migraine and panic disorder. Neurology 1994 Oct; 44 Suppl. 7: S23-27
18. Marazziti D, Toni C, Pedri S, et al. Headache, panic disorder and depression: Comorbidity or a spectrum? Neuropsychobiology 1995; 31: 125-9
19. Breslau N, Chilcoat HD, Andreski P. Further evidence on the link between migraine and neuroticism. Neurology 1996 Sep; 47: 663-7
20. Lipton RB, Stewart WF, Von Korff M. Migraine impact and functional disability. Cephalalgia 1995 Oct; 15 Suppl. 15: 4-9
21. Pryse-Phillips WEM, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Can Med Assoc J 1997 May 1; 156 (9): 1273-87
22. Capobianco DJ, Cheshire WP, Campbell JK. An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clin Proc 1996 Nov; 71: 1055-66
23. Leone M, Bussone G. Current approaches to the prophylaxis of migraine. CNS Drugs 1995 Mar; 3: 165-73
24. Lewis TA, Solomon GD. Advances in migraine management. Cleve Clin J Med 1995 May-Jun; 62: 148-55
25. Ciervo CA, Gallagher RM, Mueller L, et al. The role of diet in treated migraine patients. Headache Q 1996; 7 (4): 319-23
26. Berg MM, Braham J. Response to dietary restriction in migraine: a comparison of results in children and adults [letter]. Postgrad Med J 1994 Dec; 70: 937-8
27. van Roijen L, Essink-Bot M-L, Koopmanschap MA, et al. Societal perspective on the burden of migraine in The Netherlands. Pharmacoeconomics 1995; 7 (2): 170-9
28. Edmeads J, Findlay H, Tugwell P, et al. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993 May; 20: 131-7
29. Baischer W. Acupuncture in migraine: long-term outcome and predicting factors. Headache 1995 Sep; 35: 472-4
30. Reid GJ, McGrath PJ. Psychological treatments for migraine. Biomed Pharmacother 1996; 50: 58-63
31. Andrasik F. Behavioral management of micraine. Biomed Pharmacother 1996; 50: 52-7
32. Holroyd KA, Penzien DB. Psychosocial interventions in the management of recurrent headache disorders. 1: overview and effectiveness. Behav Med 1994; 20 (2): 53-63
33. Hermann C, Kim M, Blanchard EB. Behavioral and prophylactic pharmacological intervention studies of pediatric migraine: an exploratory meta-analysis. Pain 1995 Mar; 60: 239-55
34. Skaer TL. Clinical presentation and treatment of migraine. Clin Ther 1996 Mar-Apr; 18: 229-45
35. Clarke CE, MacMillan L, Sondhi S, et al. Economic and social impact of migraine. Q J Med 1996 Jan; 89: 77-84
36. Sumatriptan succinate prescribing information. Mosby's Complete Drug Reference 1997 Physicians GenRx, 7th ed. II-1935-II-1940
37. Tfelt-Hansen P. Prophylactic pharmacotherapy of migraine. Some practical guidelines. Neurol Clin 1997; 15: 153-65
38. Johnson ES, Kadam NP, Hylands DM, et al. Efficacy of fever-few as prophylactic treatment of migraine. BMJ 1985; 291: 569-73
39. Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265: 2831-5
40. Blakeborough P, Lloyd DK, Arnold WSG. Speed of response to sumatriptan in migraine and cluster headache. Br J Clin Res 1994; 5: 123-38
41. Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316-21
42. Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol 1991; 31: 306-13
43. Coukell AJ, Lamb HM. Sumatriptan: a pharmacoeconomic review of its use in migraine. Pharmacoeconomics 1997; 11 (5): 473-90
44. Salonen R, Ashford E, Dahlöf C. Intranasal sumatriptan for the acute treatment of migraine. J Neurol 1994 Jul; 241: 463-9
45. Ryan Jr RE, Baker CC, Elkind A, et al. Intranasal sumatriptan for acute treatment of migraine: results of two clinical studies [abstract]. Neurology 1996 Feb; 46 Suppl.: 202
46. Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31: 306-13
47. Sumatriptan prescribing information (UK). ABPI Compendium of data sheets and summaries of product characteristics. London: Datapharma Publications Limited, 395-7
48. Bates D, Ashford E, Dawson R. Subcutaneous sumatriptan during the migraine aura. Neurology 1994 Sep; 44: 1587-92
49. Bousser MG, d'Allens H, Richard A, et al. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. J Intern Med 1993; 234: 211-6
50. Facchinetti F, Bonellie G, Kangasniemi P, et al. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. Obstet Gynecol 1995 Dec; 86: 911-6
51. Gross M, Barrie M, Bates D, et al. The efficacy of sumatriptan in menstrual migraine [abstract]. Eur J Neurol 1995 Sep; 2 Suppl. I: 144-5
52. Rederich G, Rapoport A, Cutler N. Oral sumatriptan for the long-term treatment of migraine: clinical findings. Neurology 1995 Aug; 45 Suppl. 7: 15-20
53. Von Korff SR. Headache formulary for managed care organizations [letter]. Headache 1995 Jan; 35: 52-3
54. Bates D. Long-term tolerability, safety and efficacy of subcutaneous sumatriptan in migraine patients [abstract]. Eur J Neurol 1995 Sep; 2 Suppl. 1: 146
55. Rapoport AM, Visser WH, Cutler NR, et al. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology 1995 Aug; 45: 1505-9
56. Visser WH, Burggraaf J, Muller LM, et al. Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 1996 Oct; 60: 452-60
57. Nicolodi M. The problem of refractoriness to sumatriptan: does it really exist? [abstract]. Cephalalgia 1996 Aug; 16: 360
58. Solomon GD, Genzen JR, Litaker DG. Predicting response to sumatriptan. Clin Pharmacol Ther 1996 Feb; 59: 196
59. Visser WH, de Vriend RHM, Jaspers NHWM, et al. Sumatriptan - nonresponders: a survey in 366 migraine patients. Headache 1996 Sep; 36: 471-5
60. Visser WH, Jaspers NMWH, de Vriend RHM, et al. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996 Jun; 16: 264-9
61. Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 1992 May-Jun; 32: 177-84
62. Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol 1991 Sep-Oct; 31: 314-22
63. Tfelt-Hansen P, Henry P, Mulder LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995 Oct 7; 346: 923-6
64. Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996 Feb; 53: 180-4
65. Prescott L. Naratriptan provides effective migraine control. Inpharma 1997 Apr 26 (1084): 9-10
66. Visser WH, Terwindt GM, Reines SA, et al. Rizatriptan vs sumatriptan in the acute treatment of migraine: a placebo-controlled, dose-ranging study. Arch Neurol 1996 Nov; 53: 1132-7
67. Hillis WS, McIntyre PD. Sumatriptan and chest pain. Lancet 1993; 341: 1564-5
68. Brown EG, Endersby CA, Smith RN, et al. The safety and tolerability of sumatriptan: an overview. Eur Neurol 1991; 31: 339-44
69. Curtin T, Brooks AP, Roberts JA. Cardiorespiratory distress after sumatriptan given by injection [letter]. BMJ 1992; 305: 713-4
70. Ottervanger JP, Paalman HJA, Boxma GL, et al. Transmural myocardial infarction with sumatriptan. Lancet 1993; 341: 861-2
71. O'Connor P, Gladstone P. Oral sumatriptan-associated transmural myocardial infarction. Neurology 1995 (45): 2274-6
72. Imigran nasal spray. Pharm J 1997 Mar 1; 258: 318
73. Ottervanger JP, Valkenburg HA, Grobbee DE. Pattern of sumatriptan use and overuse in general practice. Eur J Clin Pharmacol 1996 Jul; 50: 353-5
74. Gaist D, Hallas J, Sindrup SH, et al. Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 1996 May; 50: 161-5
75. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992 Jul; 2: 67-76
76. Gaist D, Andersen M, Aarup A-L, et al. Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol 1997; 43: 429-33
77. Litaker DG, Solomon GD, Genzen JR. Impact of sumatriptan on clinic utilization and costs of care in migraineurs. Headache 1996 Oct; 36: 538-41
78. Langsdale T. Sumatriptan for migraine: assessing the outcomes. Inpharma 1996 Apr 20; 1033: 7-8
79. Cohen JA, Beall DG, Miller DW, et al. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. Fam Med 1996; 28: 171-7
80. Streator SE, Shearer SW. Pharmacoeconomic impact of injectable sumatriptan on migraine-associated healthcare costs. Am J Man Care 1996; 2 (2): 139-43
81. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993 Jan; 33: 29-35
82. Bosanquet N, Zammit-Lucia J. Migraine: prevention or cure? Br J Med Econ 1992; 2: 81-91
83. Cull RE, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ 1992; 2: 103-15
84. Adelman JU, Sharfman M, Johnson R, et al. Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Man Care 1996; 2 (10): 1407-16
85. Cortelli P, Dahlöf C, Bouchard J, et al. A multinational investigation of the impact of subcutaneous sumatriptan. III: workplace productivity and non-workplace activity. Pharmacoeconomics 1997; 11 Suppl. 1: 35-42
86. Gross MLP, Dowson AJ, Deavy L, et al. Impact of oral sumatriptan 50 mg on work productivity and quality of life in migraineurs. Br J Med Econ 1996; 10: 231-46
87. Mushet GR, Miller D, Clements B, et al. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache 1996 Mar; 36: 137-43
88. Cady R, Ryan R, Jhingran P, et al. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial [abstract]. Headache 1997 May; 37: 302
89. Payne K, Kozma CM, Lawrence BJ. Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine: a retrospective cost-efficacy analysis. Pharmacoeconomics 1996 Jul; 10: 59-71
90. Dahlöf CGH, Dimenäs E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995 Feb; 15: 31-6
91. Osterhaus JT, Townsend RJ, Gandek B, et al. Measuring the functional status and well-being of patients with migraine headache. Headache 1994 Jun; 34: 337-43
92. Solomon GD, Skobieranda FG, Gragg LA. Quality of life and well-being of headache patients: measurement by the Medical Outcomes Study Instrument. Headache 1993 Jul-Aug; 33: 351-8
93. Pryse-Phillips W, Findlay H, Tugwell P, et al. A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache. Can J Neurol Sci 1992 Aug; 19: 333-9
94. Boureau F, Chazot G, Emile J, et al. Comparison of subcutaneous sumatriptan with usual acute treatments for migraine. Eur Neurol 1995 Sep-Oct; 35: 264-9
95. Dahlöf C, Bouchard J, Coretelli P, et al. A multinational investigation of the impact of subcutaneous sumatriptan. II: health-related quality of life. Pharmacoeconomics 1997; II Suppl. 1: 24-34
96. Heywood J, Bouchard J, Cortelli P, et al. A multinational investigation of the impact of subcutaneous sumatriptan. I: design, methods and clinical findings. Pharmacoeconomics 1997; 11 Suppl. 1: 11-23
97. Bouchard J, Cortelli P, Dahlöf C, et al. A multinational investigation of the impact of subcutaneous sumatriptan IV: patient satisfaction. Pharmacoeconomics 1997; 11 Suppl. 1: 43-50
98. 1Dreceptor agonists. Headache Q 1996; 7 Suppl. 2: 17-20